Home siRNA SR301629
FLT3 (ID 2322) Trilencer-27 Human siRNA
- FLT3 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 2322)
- Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
- Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
- SiTran1.0: Transfection reagent designed for RNAi duplex (0.5 ml)
* These siRNA duplexes were designed to be effective against all transcriptional variants at this gene locus.
** Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping.
Also for FLT3 (Locus ID 2322)
|Amount: 2 nmol each, lyophilized||Purity: HPLC purified|
|Quality Control: Tested by ESI-MS||Sequences: Available with shipment|
|Stability: One year from date of shipment when stored at -20ºC||Shipment: Ambient|
|# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM)|
|Note: Single siRNA duplex (10nmol) can be ordered. See details at http://www.origene.com/siRNA/|
|Synonyms: CD135; FLK-2; FLK2; STK1|
|Summary: This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jul 2008]. |Performance Guranteed:
OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.
For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at firstname.lastname@example.org. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).